Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome

Leukemia Research

Volumn 35, Issue 4, 2011, Pages 522-525

  Roboz, Gail J ^a   Ritchie, Ellen K ^a   Curcio, Tania ^a   Samuel, Michael ^a   Provenzano, Juliette ^a   Segovia, Javier ^a   Christos, Paul J ^a   Mathew, Susan ^a   Allen Bard, Sandra ^a   Feldman, Eric J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Arsenic; Low dose cytarabine; MDS; Myelodysplastic syndrome

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; CYTARABINE;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACTEREMIA; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOGENETICS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FUNGEMIA; HEART ARRHYTHMIA; HEART INFARCTION; HEART TAMPONADE; HEMOPTYSIS; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LUNG HEMORRHAGE; MALE; MELENA; MONOCYTOSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SUBDURAL HEMATOMA; TORSADE DES POINTES; VAGINA BLEEDING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CYTARABINE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NAUSEA; OXIDES; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952359646     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.09.010     Document Type: Article

References (23)

1. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
2. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
3. Degos L., Castaigne S., Tilly H., Sigaux F., Daniel M.T. Treatment of leukemia with low-dose ara-C: a study of 160 cases. Semin Oncol 1985, 12:196-199.
4. Cheson B.D., Jasperse D.M., Simon R., Friedman M.A. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986, 4:1857-1864.
5. Burnett A.K., Milligan D., Prentice A.G., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124.
6. Visani G., Malagola M., Piccaluga P.P., Isidori A. Low dose ara-C for myelodysplastic syndromes: is it still a current therapy?. Leuk Lymphoma 2004, 45:1531-1538.
7. Aul C., Schneider W. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 1989, 64:1812-1818.
8. Slapak C.A., Desforges J.F., Fogaren T., Miller K.B. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol 1992, 41:178-183.
9. Nachtkamp K., Kundgen A., Strupp C., et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 2009, 33:1024-1028.
10. Miller K.B., Kim K., Morrison F.S., et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1992, 65:162-168.
11. Roboz G.J., Ritchie E.K., Curcio T., et al. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008, 113:2504-2511.
12. Schiller G.J., Slack J., Hainsworth J.D., et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006, 24:2456-2464.
13. Vey N., Bosly A., Guerci A., et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006, 24:2465-2471.
14. 3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol 2002, 116:555-563.
15. Rojewski M.T., Korper S., Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma 2004, 45:2387-2401.
16. Roboz G.J., Dias S., Lam G., et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000, 96:1525-1530.
17. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62:3893-3903.
18. Douer D., Tallman M.S. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005, 23:2396-2410.
19. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
20. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
21. Fenaux P., Ades L. Review of azacitidine trials in Intermediate-2-and high-risk myelodysplastic syndromes. Leuk Res 2009, 33(Suppl. 2):S7-11.
22. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
23. Kantarjian H.M., O'Brien S., Huang X., et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007, 109:1133-1137.